Demystifying pharmaceutical patient assistance programs
Prescription drug costs impose a significant financial burden on the United States healthcare system. Patients with chronic dermatologic diseases often require long-term and expensive prescription drugs. In an effort to expand drug availability, pharmaceutical companies fund patient assistance programs (PAPs) to assist disadvantaged patients in gaining access to high-priced brand name medications with no suitable therapeutic alternative. Patients and clinical staff often face difficulty navigating the various PAPs. Herein, we seek to explore the utility, criteria, and challenges in PAPs and provide a practical discourse for dermatologists caring for medically indigent patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
The Journal of dermatological treatment - 33(2022), 1 vom: 01. Feb., Seite 336-341 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Collier, Erin K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dermatology medications |
|---|
| Anmerkungen: |
Date Completed 15.02.2022 Date Revised 15.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/09546634.2020.1753642 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308928385 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308928385 | ||
| 003 | DE-627 | ||
| 005 | 20231225132808.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09546634.2020.1753642 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1029.xml |
| 035 | |a (DE-627)NLM308928385 | ||
| 035 | |a (NLM)32308069 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Collier, Erin K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Demystifying pharmaceutical patient assistance programs |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2022 | ||
| 500 | |a Date Revised 15.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Prescription drug costs impose a significant financial burden on the United States healthcare system. Patients with chronic dermatologic diseases often require long-term and expensive prescription drugs. In an effort to expand drug availability, pharmaceutical companies fund patient assistance programs (PAPs) to assist disadvantaged patients in gaining access to high-priced brand name medications with no suitable therapeutic alternative. Patients and clinical staff often face difficulty navigating the various PAPs. Herein, we seek to explore the utility, criteria, and challenges in PAPs and provide a practical discourse for dermatologists caring for medically indigent patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Dermatology medications | |
| 650 | 4 | |a financial assistance | |
| 650 | 4 | |a patient assistance programs | |
| 650 | 4 | |a pharmaceutical companies | |
| 650 | 4 | |a prescription drugs | |
| 650 | 7 | |a Prescription Drugs |2 NLM | |
| 700 | 1 | |a Price, Kyla N |e verfasserin |4 aut | |
| 700 | 1 | |a Hsiao, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Vivian Y |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of dermatological treatment |d 1992 |g 33(2022), 1 vom: 01. Feb., Seite 336-341 |w (DE-627)NLM088851680 |x 1471-1753 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2022 |g number:1 |g day:01 |g month:02 |g pages:336-341 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09546634.2020.1753642 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2022 |e 1 |b 01 |c 02 |h 336-341 | ||